HomeAI · summaries
Storia in 2 fonti
Xpovio mulligan in endometrial cancer comes up short as Karyopharm presses on in myelofibrosis
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in Marc | Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Pfizer takes Litfulo to regulators in vitiligo challenge to Incyte, AbbVie
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival…
- ·
endpoints.news
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm shares crater 65% after Xpovio fails Phase 3 endometrial cancer trial; company pivots to myelofibrosis label bid.
